Expression of Muscarinic Acetylcholine Receptors (M1-, M2-, M3- and M4-type) in the Neuromuscular Junction of the Newborn and Adult Rat
Overview
Pathology
Authors
Affiliations
Using intracellular recording and immunohistochemistry, we studied the presynaptic muscarinic autoreceptor subtypes controlling ACh release in the neuromuscular junctions of the newborn (3-6 days postnatal) and adult (30-40 days) rat. In the Levator auris longus muscles of both newborn and adult rats, acetylcholine release was modified by the M1-receptor selective antagonists pirenzepine (10 microM) and MT-7 (100 nM) and by the M2-receptor selective antagonists methoctramine (1 microM) and AF-DX 116 (10 microM). The M4-receptor selective antagonists tropicamide (1 microM) and MT-3 (100 nM) can also modify the neurotransmitter release in certain synapses of the newborn muscles. The neurotransmitter release was not altered by the M3-receptor selective antagonist 4-DAMP (1 microM) in the adult or newborn rats. However, we directly demonstrate by immunocytochemistry the presence of these receptors in the motor endplates and conclude that M1-, M2-, M3- and M4-type muscarinic receptors are present in all the neuromuscular junctions of the rat muscle both in newborn and adult animals. These receptors may be located in the perisynaptic glial cell as well as at the nerve terminals.
Polishchuk A, Cilleros-Mane V, Balanya-Segura M, Just-Borras L, Fornies-Marine A, Silvera-Simon C Cell Commun Signal. 2024; 22(1):371.
PMID: 39044222 PMC: 11265447. DOI: 10.1186/s12964-024-01735-2.
Muscarinic Cholinoreceptors in Skeletal Muscle: Localization and Functional Role.
Kovyazina I, Khamidullina A Acta Naturae. 2024; 15(4):44-55.
PMID: 38234599 PMC: 10790362. DOI: 10.32607/actanaturae.25259.
A multilevel screening pipeline in zebrafish identifies therapeutic drugs for GAN.
Lescouzeres L, Hassen-Khodja C, Baudot A, Bordignon B, Bomont P EMBO Mol Med. 2023; 15(7):e16267.
PMID: 37144692 PMC: 10331585. DOI: 10.15252/emmm.202216267.
Mantilla C, Ermilov L, Greising S, Gransee H, Zhan W, Sieck G J Neurophysiol. 2023; 129(4):781-792.
PMID: 36883761 PMC: 10069962. DOI: 10.1152/jn.00015.2023.
Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study.
Ceccanti M, Libonati L, Ruffolo G, Cifelli P, Moret F, Frasca V Front Pharmacol. 2022; 13:982434.
PMID: 36052140 PMC: 9424766. DOI: 10.3389/fphar.2022.982434.